EGb 761® (Tanakan®)

DRUG3 trials

Sponsors

Ipsen

Conditions

Alzheimer DiseaseMemory Disorders, Age-RelatedMultiple Sclerosis, Relapsing-RemittingRetention Disorders, Cognitive

Phase 2

Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease

TerminatedNCT00500500

IpsenAlzheimer Disease

Start: 2005-07-31End: 2008-04-30Updated: 2023-06-26

Phase 3

Study on the Effectiveness of EGb 761® vs Placebo Used for Cognitive Impairment in Patients With Multiple Sclerosis

CompletedNCT00276341

IpsenMultiple Sclerosis, Relapsing-Remitting

Start: 2003-08-26End: 2005-12-08Updated: 2024-03-07

Phase 4

A Study of EGb 761® (Tanakan®) in Dementia of Alzheimer Type Onset in Patients Suffering From Memory Complaints

CompletedNCT00276510

IpsenMemory Disorders, Age-Related, Retention Disorders, Cognitive

Start: 2002-02-28End: 2009-11-30Updated: 2019-01-15

Related Papers

Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial.

2012-09-06213 citations